

Vinay Prasad

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5320299/vinay-prasad-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

290
papers

5,613
citations

35
h-index

69
g-index

334
ext. papers

7,530
ext. citations

8.3
avg, IF

7.2
L-index

#	Paper	IF	Citations
290	An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC).. <i>BMC Cancer</i> , 2022 , 22, 70	4.8	
289	Retrospective comparative effectiveness research: will changing the analytical methods change the results?. <i>International Journal of Cancer</i> , 2022 ,	7.5	1
288	Reporting of Physicians' or Investigators' Choice of Treatment in Oncology Randomized Clinical Trials.. <i>JAMA Network Open</i> , 2022 , 5, e2144770	10.4	1
287	The accelerated approval pathway in oncology: Balancing the benefits and potential harms.. <i>Journal of Cancer Policy</i> , 2022 , 32, 100323	1	0
286	Artificial intelligence and magnetic resonance imaging may not make cancer screening better.. <i>Journal of Cancer Policy</i> , 2022 , 31, 100314	1	
285	A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers.. <i>Journal of Cancer Policy</i> , 2022 , 31, 100319	1	
284	Recommendation Reversals in Gastroenterology Clinical Practice Guidelines.. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022 , 5, 98-99	0.5	
283	Frequency of survival to hospital discharge after cardiopulmonary resuscitation on FOX TV's The Resident.. <i>European Journal of Emergency Medicine</i> , 2022 , 29, 142-143	2.3	1
282	The Kardashian Index: a study of researchers' opinions on twitter 2014-2021. <i>Scientometrics</i> , 2022 , 127, 1923-1930	3	
281	Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours.. <i>European Journal of Cancer</i> , 2022 , 164, 95-104	7.5	
280	Post-protocol therapy and informative censoring in the CANDOR study.. <i>Lancet Oncology</i> , 2022 , 23, e97	21.7	
279	Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.. <i>JAMA Network Open</i> , 2022 , 5, e222265	10.4	3
278	Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti-PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102904	2.2	1
277	The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.. <i>Translational Oncology</i> , 2022 , 18, 101374	4.9	5
276	Characteristics of oncology podcasts: Attitudes, speakers, conflicts.. <i>Journal of Cancer Policy</i> , 2022 , 32, 100329	1	1
275	Tebentafusp in first-line melanoma trials: An outperforming outlier.. <i>Translational Oncology</i> , 2022 , 20, 101408	4.9	2
274	The effect of hospital visitor policies on patients, their visitors, and healthcare providers during the COVID-19 pandemic: a systematic review.. <i>American Journal of Medicine</i> , 2022 ,	2.4	5

273	Accelerated approval requirements for lurbinectedin.. <i>Lancet Oncology, The</i> , 2022 , 23, e206	21.7	0
272	Multiplicity: When Many Analytic Plans Are Applied or Many Redundant Studies are Run, False Positive Results are Ensured.. <i>European Journal of Clinical Investigation</i> , 2022 , e13802	4.6	0
271	FDA precedents in drug approvals: Contradiction in promoting more treatment options.. <i>European Journal of Cancer</i> , 2022 , 169, 123-125	7.5	
270	Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials.. <i>JAMA Network Open</i> , 2022 , 5, e2212327	10.4	0
269	Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.. <i>JAMA Network Open</i> , 2021 , 4, e2138793	10.4	12
268	Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021 ,	4.5	
267	Elacestrant in metastatic breast cancer: Is the "standard of care" meeting standard requirements?. <i>Translational Oncology</i> , 2021 , 15, 101273	4.9	
266	The frequency of assessment of progression in randomized oncology clinical trials. <i>Cancer Reports</i> , 2021 , e1527	1.5	0
265	Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020. <i>JAMA Network Open</i> , 2021 , 4, e2135123	10.4	1
264	Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study. <i>Cancer</i> , 2021 , 128, 311	6.4	0
263	Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015-2020.. <i>Journal of Cancer Policy</i> , 2021 , 30, 100311	1	0
262	Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm. <i>Translational Oncology</i> , 2021 , 15, 101248	4.9	4
261	Approval and Coverage of Cancer Drugs in England, Canada, and the US. <i>JAMA Internal Medicine</i> , 2021 , 181, 509-510	11.5	2
260	Pembrolizumab for Non-Muscle-Invasive Bladder Cancer-A Costly Therapy in Search of Evidence. <i>JAMA Oncology</i> , 2021 , 7, 501-502	13.4	2
259	Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. <i>Lancet Haematology,the</i> , 2021 , 8, e299-e304	14.6	3
258	Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100149	1.4	0
257	The regulatory saga of fedratinib. <i>Journal of Oncology Pharmacy Practice</i> , 2021 , 27, 1248-1250	1.7	0
256	Assessment of New Molecular Entities Approved for Cancer Treatment in 2020. <i>JAMA Network Open</i> , 2021 , 4, e2112558	10.4	1

255	N of 1 Data Sharing: The Impact of Data Sharing within the Hematology-Oncology Drug Products Division of the US FDA. <i>Trends in Cancer</i> , 2021 , 7, 395-399	12.5	
254	Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. <i>JAMA Oncology</i> , 2021 , 7, 728-734	13.4	30
253	Multiple myeloma triplet therapies: baseline characteristics and control groups. <i>Lancet, The</i> , 2021 , 397, 1620-1621	40	
252	Accurate accounting of caplacizumab cost effectiveness. <i>Lancet Haematology,the</i> , 2021 , 8, e315	14.6	0
251	Reliable, cheap, fast and few: What is the best study for assessing medical practices? Randomized controlled trials or synthetic control arms?. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13580	4.6	0
250	Industry payments to US physicians for cancer therapeutics: An analysis of the 2016-2018 open payments datasets.. <i>Journal of Cancer Policy</i> , 2021 , 28, 100283	1	1
249	The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2793-2795	1.9	4
248	The Oncologic Drugs Advisory Committee Votes of April 2021-Implications for the Fate of Accelerated Approval. <i>JAMA Oncology</i> , 2021 , 7, 1607-1609	13.4	10
247	Drug Approvals in Hepatocellular Carcinoma-Filling the Nonexistent Gap?. <i>JAMA Oncology</i> , 2021 , 7, 173-174	13.4	0
246	The response rate of alternative treatments for drugs approved on the basis of response rate. <i>International Journal of Cancer</i> , 2021 , 148, 713-722	7.5	5
245	Persistent challenges with treating multiple myeloma early. <i>Blood</i> , 2021 , 137, 456-458	2.2	8
244	Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 7-8	19.4	4
243	Considering benefit and risk before routinely recommending SpaceOAR. <i>Lancet Oncology, The</i> , 2021 , 22, 11-13	21.7	14
242	Application of ASCO Value Framework to Treatment Advances in Hepatocellular Carcinoma. <i>JCO Oncology Practice</i> , 2021 , 17, e461-e468	2.3	1
241	Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018. <i>JAMA Internal Medicine</i> , 2021 , 181, 162-167	11.5	14
240	Old-fashioned Intelligence Will Always Be Needed in Medicine. <i>European Urology Focus</i> , 2021 , 7, 685-686	5.1	
239	The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years. <i>JAMA Oncology</i> , 2021 , 7, 1569-1570	13.4	2
238	Has the Current Oncology Value Paradigm Forgotten Patients' Time?: Too Little of a Good Thing. <i>JAMA Oncology</i> , 2021 ,	13.4	2

237	An Analysis of 5 Years of Randomized Trials in Gastroenterology and Hepatology Reveals 52 Medical Reversals. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	0
236	Idecabtagene vicleucel: questions regarding the appropriate role and cost. <i>British Journal of Haematology</i> , 2021 ,	4.5	1
235	After COVID-19, telemedicine may be used in addition to usual care and not in lieu of: Implications for health systems. <i>International Journal of Cancer</i> , 2021 , 149, 1723-1724	7.5	
234	The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009-2018. <i>BMC Cancer</i> , 2021 , 21, 889	4.8	4
233	Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients diverge. <i>European Journal of Cancer</i> , 2021 , 155, 163-167	7.5	0
232	New drugs and options can enhance patient outcomes: But can they also erode them?. <i>European Journal of Cancer</i> , 2021 , 154, 1-3	7.5	1
231	Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review. <i>JAMA Network Open</i> , 2021 , 4, e2124728	10.4	0
230	The FDA's latest move to expand eligibility for oncology trials - a double-edged sword?. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 745-746	19.4	1
229	Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COVS.2.S vaccination. <i>Frontiers of Medicine</i> , 2021 , 1	12	0
228	The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2305-2308	6.4	
227	Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021 , 156, 164-174	7.5	0
226	How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond. <i>European Journal of Cancer</i> , 2021 , 157, 68-70	7.5	3
225	Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , 2021 , 139, 80-86	5.7	3
224	Where are randomized trials necessary: Are smoking and parachutes good counterexamples?. <i>European Journal of Clinical Investigation</i> , 2021 , e13730	4.6	0
223	Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing. <i>European Journal of Cancer</i> , 2020 , 141, 152-161	7.5	5
222	Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?. <i>Cancer</i> , 2020 , 126, 4087-4088	6.4	5
221	Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration. <i>JAMA Internal Medicine</i> , 2020 , 180, 1108-1115	11.5	29
220	Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs. <i>JAMA Network Open</i> , 2020 , 3, e200423	10.4	52

219	News Coverage of the American Cancer Society's Update to Colorectal Cancer Screening Guidelines. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 617-618	6.4	1
218	Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials. <i>JAMA Network Open</i> , 2020 , 3, e200363	10.4	15
217	Shifting, overlapping and expanding use of "precision oncology" terminology: a retrospective literature analysis. <i>BMJ Open</i> , 2020 , 10, e036357	3	4
216	A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer. <i>Trends in Cancer</i> , 2020 , 6, 736-738	12.5	3
215	US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation. <i>Cancer</i> , 2020 , 126, 4270-4272	6.4	1
214	Medical Reversals in Family Practice: A Review. <i>Current Therapeutic Research</i> , 2020 , 92, 100579	2.4	1
213	Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administration's Actions. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 424-426	6.4	4
212	Statistical significance and clinical evidence - Authors' reply. <i>Lancet Oncology, The</i> , 2020 , 21, e119	21.7	1
211	Replacing the NCCN's Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?. <i>Pharmacoeconomics</i> , 2020 , 38, 729-731	4.4	2
210	Comparison of Drugs Used for Adjuvant and Metastatic Therapy of Colon, Breast, and Non-Small Cell Lung Cancers. <i>JAMA Network Open</i> , 2020 , 3, e202488	10.4	4
209	Comparison of Industry Payments in 2017 With Annual Salary in a Cohort of Academic Oncologists. <i>JAMA Internal Medicine</i> , 2020 , 180, 797-799	11.5	5
208	FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019. <i>JAMA Internal Medicine</i> , 2020 , 180, 912-914	11.5	25
207	Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 428-433	7.3	5
206	Characteristics of Public Comments Submitted to State Health Technology Assessment Programs in Oregon and Washington. <i>JAMA Internal Medicine</i> , 2020 , 180, 329-331	11.5	2
205	A method to determine if more than surrogate outcomes were improved: The EMR glitch experiment. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 19-22	5.1	
204	The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab. <i>JAMA Internal Medicine</i> , 2020 , 180, 315-317	11.5	2
203	Examining the Use of Real-World Evidence in the Regulatory Process. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 843-852	6.1	29
202	Medical reversals in low- and middle-income countries. <i>International Journal of Health Planning and Management</i> , 2020 , 35, 631-638	2.2	1

201	Concerning survival signal for eltrombopag in MDS/AML. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1002-1003	1.9	
200	Phase I trials and therapeutic intent in the age of precision oncology: What is a patient's chance of response?. <i>European Journal of Cancer</i> , 2020 , 139, 20-26	7.5	5
199	Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2020 , 96, 106420	2.7	3
198	Response to Comment on "Replacing the NCCN's Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?". <i>Pharmacoeconomics</i> , 2020 , 38, 895-896	4.4	1
197	Estimation of US patients with cancer who may respond to cytotoxic chemotherapy. <i>Future Science OA</i> , 2020 , 6, FSO600	2.7	3
196	Drug repurposing in oncology - Authors' reply. <i>Lancet Oncology, The</i> , 2020 , 21, e544	21.7	1
195	Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. <i>BMJ Evidence-Based Medicine</i> , 2020 ,	2.7	8
194	Frequency of Medical Reversal Among Published Randomized Controlled Trials Assessing Cardiopulmonary Resuscitation (CPR). <i>Mayo Clinic Proceedings</i> , 2020 , 95, 889-910	6.4	1
193	Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy. <i>Lancet Oncology, The</i> , 2020 , 21, 1134-1136	21.7	9
192	Are Observational, Real-World Studies Suitable to Make Cancer Treatment Recommendations?. <i>JAMA Network Open</i> , 2020 , 3, e2012119	10.4	9
191	The evidence landscape in precision medicine. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	11
190	An Empirical Analysis of Noninferiority Studies in Oncology: Are They Good Enough?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 161-167	7.3	
189	A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. <i>ELife</i> , 2019 , 8,	8.9	47
188	Association between conflict of interest and published position on tumor-treating fields for the treatment of glioblastoma. <i>Journal of Cancer Policy</i> , 2019 , 21, 100189	1	8
187	Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice?. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 951-956	6.4	1
186	An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. <i>JAMA Internal Medicine</i> , 2019 , 179, 915-921	11.5	55
185	Real-world Evidence-What Does It Really Mean?. <i>JAMA Oncology</i> , 2019 , 5, 781-783	13.4	26
184	Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals. <i>JAMA Network Open</i> , 2019 , 2, e193981	10.4	4

183	Should Evidence Come with an Expiration Date?. <i>Journal of General Internal Medicine</i> , 2019 , 34, 1356-1357		4
182	Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. <i>JAMA Network Open</i> , 2019 , 2, e192535	10.4	382
181	Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration. <i>JAMA Oncology</i> , 2019 , 5, 887-892	13.4	43
180	Testing for blinding in sham-controlled studies for procedural interventions: the third-party video method. <i>Cmaj</i> , 2019 , 191, E272-E273	3.5	2
179	Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials. <i>JAMA Internal Medicine</i> , 2019 , 179, 642-647	11.5	44
178	A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 2303-2311	4.9	6
177	A reality check of the accelerated approval of immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 656-658	19.4	17
176	Registration studies - when should patients be deemed ineligible for aggressive therapy?. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 333-334	19.4	2
175	Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib. <i>JAMA Network Open</i> , 2019 , 2, e1916091	10.4	5
174	Multiplicity in oncology randomised controlled trials: a threat to medical evidence?. <i>Lancet Oncology, The</i> , 2019 , 20, 1638-1640	21.7	6
173	Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours. <i>Current Oncology</i> , 2019 , 26, e791-e792	2.8	2
172	Where Does the Blame for High Health Care Costs Go? An Empirical Analysis of Newspaper and Journal Articles Criticizing Health Care Costs. <i>American Journal of Medicine</i> , 2019 , 132, 718-721	2.4	2
171	A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. <i>European Journal of Cancer</i> , 2019 , 106, 196-211	7.5	80
170	PFO closure for secondary stroke prevention: is the discussion closed?. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 46, 74-76	5.1	2
169	Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology. <i>JAMA Oncology</i> , 2018 , 4, 1093-1098	13.4	169
168	Assessing Pharmaceutical Research and Development Costs-Reply. <i>JAMA Internal Medicine</i> , 2018 , 178, 588-589	11.5	4
167	The relation between publication rate and financial conflict of interest among physician authors of high-impact oncology publications: an observational study. <i>CMAJ Open</i> , 2018 , 6, E57-E62	2.5	8
166	Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes. <i>CMAJ Open</i> , 2018 , 6, E31-E38	2.5	18

165	Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers. <i>JAMA Oncology</i> , 2018 , 4, 157-158	13.4	79
164	Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study. <i>BMJ, The</i> , 2018 , 360, k668	5.9	18
163	Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy. <i>JAMA Oncology</i> , 2018 , 4, 994-996	13.4	57
162	Concerns About the Approval of Nusinersen Sodium by the US Food and Drug Administration. <i>JAMA Internal Medicine</i> , 2018 , 178, 743-744	11.5	6
161	Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 11-12	19.4	117
160	A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. <i>European Journal of Cancer</i> , 2018 , 101, 143-151	7.5	14
159	Inconsistent Reporting of Potential Conflicts of Interest. <i>JAMA Pediatrics</i> , 2018 , 172, 886	8.3	
158	Why is research in early-stage cancer research so low?. <i>Journal of Cancer Policy</i> , 2018 , 17, 4-8	1	1
157	Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies-Reply. <i>JAMA Oncology</i> , 2018 , 4, 1300-1301	13.4	1
156	Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy-Reply. <i>JAMA Pediatrics</i> , 2018 , 172, 701-703	8.3	1
155	The US Food and Drug Administration's use of pathologic complete response as regulatory endpoint: Did it pay off?. <i>Journal of Cancer Policy</i> , 2018 , 16, 49-51	1	1
154	Inconsistent Reporting of Potential Conflicts of Interest. <i>JAMA Internal Medicine</i> , 2018 , 178, 1424-1425	11.5	0
153	A pooled analysis of published, basket trials in cancer medicine. <i>European Journal of Cancer</i> , 2018 , 101, 244-250	7.5	12
152	Overall Survival vs Disease-Specific Survival-Reply. <i>JAMA Oncology</i> , 2018 , 4, 586-587	13.4	3
151	Unanticipated Outcomes: A Medical Memoir A Book Review. <i>JAMA Internal Medicine</i> , 2018 , 178, 11	11.5	3
150	Meaningful and Accurate Disclosure of Conflict of Interest at the ASTRO National Meeting: A Need for Reassessment of Current Policies. <i>Journal of Oncology Practice</i> , 2018 , JOP1800121	3.1	3
149	Moving Precision Oncology Forward Amid Myths and Misconceptions-Reply. <i>JAMA Oncology</i> , 2018 , 4, 1790	13.4	
148	Addendum: Low-value approvals and high prices might incentivize ineffective drug development. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 787	19.4	

147	Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 633-635	3.9	8
146	Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?. <i>European Journal of Cancer</i> , 2018 , 104, 252-253	7.5	4
145	Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy-Reply. <i>JAMA Oncology</i> , 2018 , 4, 1785-1786	13.4	8
144	Diagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were. <i>BMJ, The</i> , 2018 , 362, k3783	5.9	6
143	Inconsistent Reporting of Potential Conflicts of Interest. <i>JAMA Oncology</i> , 2018 , 4, 1439	13.4	0
142	Eliminating MRD - FDA approval of blinatumomab for B-ALL in complete remission. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 727-728	19.4	5
141	Improving observational studies in the era of big data. <i>Lancet, The</i> , 2018 , 392, 716-717	4.0	20
140	Choice of control group in randomised trials of cancer medicine: are we testing trivialities?. <i>Lancet Oncology, The</i> , 2018 , 19, 1150-1152	21.7	7
139	Direct-to-Consumer Genetic Testing: The Implications of the US FDA's First Marketing Authorization for BRCA Mutation Testing. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 2377-2378	27.4	39
138	Low-value approvals and high prices might incentivize ineffective drug development. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 399-400	19.4	16
137	Financial Conflicts of Interest Among Hematologist-Oncologists on Twitter. <i>JAMA Internal Medicine</i> , 2017 , 177, 425-427	11.5	28
136	Drugs that lack single-agent activity: are they worth pursuing in combination?. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 193-194	19.4	17
135	What constitutes an "unmet medical need" in oncology? An empirical evaluation of author usage in the biomedical literature. <i>Seminars in Oncology</i> , 2017 , 44, 8-12	5.5	10
134	Pharmaceutical Marketing for Rare Diseases: Regulating Drug Company Promotion in an Era of Unprecedented Advertisement. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 2479-2480	27.4	8
133	Combining drugs and extending treatment - a PFS end point is not sufficient. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 521-522	19.4	10
132	The high price of anticancer drugs: origins, implications, barriers, solutions. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 381-390	19.4	178
131	Use of word "unprecedented" in the media coverage of cancer drugs: Do "unprecedented" drugs live up to the hype?. <i>Journal of Cancer Policy</i> , 2017 , 14, 16-20	1	1
130	Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?. <i>BMC Medicine</i> , 2017 , 15, 134	11.4	112

129	A further strategy to combat the high price of anticancer drugs. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 629	19.4	1
128	Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. <i>JAMA Internal Medicine</i> , 2017 , 177, 1569-1575	11.5	206
127	Conflicts of interest in Twitter. <i>Lancet Haematology,the</i> , 2017 , 4, e408-e409	14.6	12
126	Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 653-654	19.4	12
125	Overestimating the Benefit of Cancer Drugs. <i>JAMA Oncology</i> , 2017 , 3, 1737-1738	13.4	5
124	Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. <i>Seminars in Oncology</i> , 2017 , 44, 132-135	5.5	64
123	Is "Do Everything!" Always Appropriate?-Reply. <i>JAMA Oncology</i> , 2017 , 3, 1588	13.4	1
122	Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals. <i>Blood Cancer Journal</i> , 2017 , 7, 637	7	3
121	Limitations Concerning the Association of Physician Sex and Patient Outcomes. <i>JAMA Internal Medicine</i> , 2017 , 177, 1058	11.5	2
120	Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?. <i>Cancer</i> , 2017 , 123, 3872-3874	6.4	2
119	The Rising Price of Cancer Drugs-A New Old Problem?. <i>JAMA Oncology</i> , 2017 , 3, 277-278	13.4	15
118	Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World. <i>JAMA Oncology</i> , 2017 , 3, 889-890	13.4	22
117	Taking Care of Our Friends and Neighbors: DeVita's The Death of Cancer and the Challenge of Letting Go. <i>JAMA Oncology</i> , 2017 , 3, 16-17	13.4	2
116	Clinically meaningful benefit: real world use compared against the American and European guidelines. <i>Blood Cancer Journal</i> , 2017 , 7, 645	7	4
115	Effect of the American Society of Clinical Oncology's Conflict of Interest Policy on Information Overload. <i>JAMA Oncology</i> , 2016 , 2, 1653-1654	13.4	11
114	Wearables, Smartphones and Novel Anticoagulants: We Will Treat More Atrial Fibrillation, but Will Patients Be Better Off?. <i>Journal of General Internal Medicine</i> , 2016 , 31, 1367-1368	4	2
113	Future jobs of FDA's haematology-oncology reviewers. <i>BMJ, The</i> , 2016 , 354, i5055	5.9	9
112	Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies. <i>Oncologist</i> , 2016 , 21, 1031-2	5.7	4

111	Blood-Based Screening for Colon Cancer: A Disruptive Innovation or Simply a Disruption?. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 2519-20	27.4	19
110	The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 707-12	6.4	14
109	Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting. <i>Oncologist</i> , 2016 , 21, 261-8	5.7	19
108	Precision oncology: origins, optimism, and potential. <i>Lancet Oncology, The</i> , 2016 , 17, e81-e86	21.7	130
107	In Reply--Is There a Need for "Bias Police" in Industry-Sponsored Research?. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 121	6.4	
106	Characteristics and Conflicts of Public Speakers at Meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration. <i>JAMA Internal Medicine</i> , 2016 , 176, 389-91	11.5	20
105	Application of Medicare's New Technology Add-on Payment Program for Blinatumomab. <i>JAMA Oncology</i> , 2016 , 2, 165-6	13.4	3
104	Why cancer screening has never been shown to "save lives"--and what we can do about it. <i>BMJ, The</i> , 2016 , 352, h6080	5.9	66
103	The Use of Superlatives in Cancer Research. <i>JAMA Oncology</i> , 2016 , 2, 139-41	13.4	41
102	Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?. <i>European Journal of Heart Failure</i> , 2016 , 18, 128-32	12.3	6
101	Industry Funding of Cancer Patient Advocacy Organizations. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 1668-1670	6.4	20
100	Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs. <i>Mayo Clinic Proceedings</i> , 2016 ,	6.4	59
99	Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials?. <i>Medical Hypotheses</i> , 2016 , 93, 71-3	3.8	1
98	ASCO Plenary Sessions: impact, legacy, future. <i>Seminars in Oncology</i> , 2016 , 43, 321-6	5.5	3
97	Reply to Dr. Leon: true but unrelated. <i>Journal of Clinical Epidemiology</i> , 2016 , 75, 127	5.7	0
96	Balancing Accelerated Approval for Drugs With Accelerated Withdrawal--Reply. <i>JAMA Internal Medicine</i> , 2016 , 176, 567	11.5	
95	Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 271-2	27.4	21
94	Same Data; Different Interpretations. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3729-3732	2.2	5

93	Perspective: The precision-oncology illusion. <i>Nature</i> , 2016 , 537, S63	50.4	185
92	Precision medicine in acute myeloid leukemia: Hope, hype or both?. <i>Leukemia Research</i> , 2016 , 48, 73-7	2.7	8
91	Non-inferiority trials: why oncologists must remain wary. <i>Lancet Oncology, The</i> , 2015 , 16, 364-6	21.7	17
90	Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis. <i>JAMA Oncology</i> , 2015 , 1, 787-95	13.4	57
89	The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. <i>JAMA Internal Medicine</i> , 2015 , 175, 1389-98	11.5	198
88	Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals. <i>JAMA Internal Medicine</i> , 2015 , 175, 1992-4	11.5	188
87	Pricing and Value of Cancer Drugs--Reply. <i>JAMA Oncology</i> , 2015 , 1, 842-3	13.4	
86	Meta-Analyses of Statin Therapy for Primary Prevention Do Not Answer Key Questions: An Empirical Appraisal of 5 Years of Statin Meta-Analyses. <i>American Journal of Cardiovascular Drugs</i> , 2015 , 15, 379-86	4	1
85	Multiplying therapies and reducing toxicity in metastatic melanoma. <i>Cancer Biology and Therapy</i> , 2015 , 16, 1014-8	4.6	9
84	Characteristics of Exceptional or Super Responders to Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 1639-49	6.4	27
83	Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov. <i>European Journal of Cancer</i> , 2015 , 51, 2718-23	7.5	3
82	Response. <i>Chest</i> , 2015 , 148, e31-e32	5.3	
81	How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses. <i>Blood</i> , 2015 , 126, 1860-1	2.2	14
80	Authorship Inflation in Medical Publications. <i>Inquiry (United States)</i> , 2015 , 52,	1.4	28
79	Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute. <i>Oncologist</i> , 2015 , 20, 1344-6	5.7	
78	Emphasizing unique strengths and eliminating redundancy for research in low-income and middle-income countries: Lessons from a South American country. <i>Cancer</i> , 2015 , 121, 2668-70	6.4	0
77	Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. <i>JAMA Oncology</i> , 2015 , 1, 539-40	13.4	201
76	Mortality and treatment patterns among patients hospitalized with acute cardiovascular conditions during dates of national cardiology meetings. <i>JAMA Internal Medicine</i> , 2015 , 175, 237-44	11.5	36

75	Primary chemoprevention of breast cancer: Are the adverse effects too burdensome?. <i>Cmaj</i> , 2015 , 187, E276-E278	3.5	3
74	Use of the Word "Cure" in the Oncology Literature. <i>American Journal of Hospice and Palliative Medicine</i> , 2015 , 32, 477-83	2.6	8
73	Distinctive clinical characteristics of malignant mesothelioma in young patients. <i>Oncotarget</i> , 2015 , 6, 16766-73	3.3	31
72	But how many people died? Health outcomes in perspective. <i>Cleveland Clinic Journal of Medicine</i> , 2015 , 82, 146-50	2.8	5
71	Disease specific productivity of american cancer hospitals. <i>PLoS ONE</i> , 2015 , 10, e0121233	3.7	
70	Long-term effects of the 2003 ACGME resident duty hour reform on hospital mortality. <i>Mayo Clinic Proceedings</i> , 2014 , 89, 1023-5	6.4	0
69	The Peltzman effect and compensatory markers in medicine. <i>Healthcare</i> , 2014 , 2, 170-172	1.8	6
68	Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1620-9	2.2	45
67	Balloon brachytherapy for breast cancer prove that it works? Or, prove that it doesn't?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 1353-7	4.9	
66	Does the declining lethality of gunshot injuries mask a rising epidemic of gun violence in the United States?. <i>Journal of General Internal Medicine</i> , 2014 , 29, 1065-9	4	27
65	The declining demand for hospital care as a rationale for duty hour reform. <i>Journal of General Internal Medicine</i> , 2014 , 29, 1400-3	4	3
64	Why do we continue to adopt medical practices based on pathophysiology alone when we should be insisting on clinical trials?. <i>Journal of Clinical Epidemiology</i> , 2014 , 67, 361-3	5.7	9
63	Regarding empiricism and rationalism in medicine and 2 nd medical worldviews. <i>Mayo Clinic Proceedings</i> , 2014 , 89, 137	6.4	0
62	Observational studies cannot justify the inferior vena cava filter. <i>American Journal of Medicine</i> , 2014 , 127, e15	2.4	2
61	The misguided ethics of crossover trials. <i>Contemporary Clinical Trials</i> , 2014 , 37, 167-9	2.3	27
60	The reply. <i>American Journal of Medicine</i> , 2014 , 127, e21	2.4	3
59	Statins, primary prevention, and overall mortality. <i>Annals of Internal Medicine</i> , 2014 , 160, 867-9	8	3
58	Rebuttal from Dr Rho et al. <i>Chest</i> , 2014 , 145, 943-4	5.3	

57	Counterpoint: were industry-sponsored roflumilast trials appropriate? No. <i>Chest</i> , 2014 , 145, 939-42	5.3	6
56	US News and World Report cancer hospital rankings: do they reflect measures of research productivity?. <i>PLoS ONE</i> , 2014 , 9, e107803	3.7	28
55	Comparative effectiveness questions in oncology. <i>New England Journal of Medicine</i> , 2014 , 370, 1478-81	59.2	34
54	Modern drug development: which patients should come first?. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 2619-20	27.4	5
53	Further thoughts on why there are good data supporting the inferior vena cava filter. <i>JAMA Internal Medicine</i> , 2014 , 174, 164-5	11.5	
52	The withdrawal of drugs for commercial reasons: the incomplete story of tositumomab. <i>JAMA Internal Medicine</i> , 2014 , 174, 1887-8	11.5	26
51	It is time to stop screening for prostate cancer. <i>JAMA Internal Medicine</i> , 2014 , 174, 1841-2	11.5	1
50	The accelerated approval of oncologic drugs: lessons from ponatinib. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 353-4	27.4	43
49	The reply. <i>American Journal of Medicine</i> , 2014 , 127, e15	2.4	
48	Media coverage of medical journals: do the best articles make the news?. <i>PLoS ONE</i> , 2014 , 9, e85355	3.7	32
47	Can a resident's publication record predict fellowship publications?. <i>PLoS ONE</i> , 2014 , 9, e90140	3.7	8
46	The inferior vena cava filter: how could a medical device be so well accepted without any evidence of efficacy?. <i>JAMA Internal Medicine</i> , 2013 , 173, 493-5; discussion 495	11.5	32
45	Open issues with open access publication. <i>American Journal of Medicine</i> , 2013 , 126, 563-4	2.4	11
44	Duty hour reform in a shifting medical landscape. <i>Journal of General Internal Medicine</i> , 2013 , 28, 1238-40		6
43	Treatment of moderate to severe hidradenitis suppurativa. <i>Annals of Internal Medicine</i> , 2013 , 159, 72	8	2
42	Persistent reservations against the premedical and medical curriculum. <i>Perspectives on Medical Education</i> , 2013 , 2, 335-9	4.3	2
41	In reply I-reversal of medical practices. <i>Mayo Clinic Proceedings</i> , 2013 , 88, 1183-4	6.4	3
40	The reply. <i>American Journal of Medicine</i> , 2013 , 126, e45	2.4	

39	Observational studies often make clinical practice recommendations: an empirical evaluation of authors' attitudes. <i>Journal of Clinical Epidemiology</i> , 2013 , 66, 361-366.e4	5.7	45
38	A decade of reversal: an analysis of 146 contradicted medical practices. <i>Mayo Clinic Proceedings</i> , 2013 , 88, 790-8	6.4	205
37	Why randomized controlled trials are needed to accept new practices: 2 medical worldviews. <i>Mayo Clinic Proceedings</i> , 2013 , 88, 1046-50	6.4	9
36	Prespecified falsification end points: can they validate true observational associations?. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 241-2	27.4	150
35	Taking care of sick patients. <i>Cmaj</i> , 2013 , 185, 1008	3.5	
34	Why resident physicians stay late. <i>Cmaj</i> , 2013 , 185, 1184	3.5	
33	Routine noninvasive testing and highly sensitive troponin immunoassays--reply. <i>JAMA Internal Medicine</i> , 2013 , 173, 833-4	11.5	
32	The inferior vena cava filter--reply. <i>JAMA Internal Medicine</i> , 2013 , 173, 1754-5	11.5	
31	Characteristics of cluster randomized trials: are they living up to the randomized trial?. <i>JAMA Internal Medicine</i> , 2013 , 173, 313-5	11.5	5
30	Firearm legislation and gun-related fatalities. <i>JAMA Internal Medicine</i> , 2013 , 173, 2011	11.5	1
29	Evaluating health system processes with randomized controlled trials. <i>JAMA Internal Medicine</i> , 2013 , 173, 1279-80	11.5	5
28	Double-crossed: why crossover in clinical trials may be distorting medical science. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 625-7	7.3	9
27	Probiotics, prebiotics, synbiotics and naturally fermented foods: why more may be more. <i>Annals of Gastroenterology</i> , 2013 , 26, 277-278	2.2	3
26	Powering cancer screening for overall mortality. <i>Ecancermedicalscience</i> , 2013 , 7, ed27	2.7	1
25	The overdiagnosis of pneumonia. <i>Cleveland Clinic Journal of Medicine</i> , 2013 , 80, 616-8	2.8	4
24	Chest pain in the emergency department: the case against our current practice of routine noninvasive testing. <i>Archives of Internal Medicine</i> , 2012 , 172, 1506-9		38
23	Publication trends among internal medicine residents and graduates. <i>American Journal of Medicine</i> , 2012 , 125, 939-44	2.4	10
22	Reversals of established medical practices: evidence to abandon ship. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 37-8	27.4	102

21	The diagnosis and treatment of pulmonary embolism: a metaphor for medicine in the evidence-based medicine era. <i>Archives of Internal Medicine</i> , 2012 , 172, 955-8		24
20	A medical burden of proof: Towards a new ethic. <i>BioSocieties</i> , 2012 , 7, 72-87	1.5	15
19	Raise the bar even higher for primary prevention interventions-reply. <i>Archives of Internal Medicine</i> , 2012 , 172, 1352-3		
18	Cardiovascular primary prevention: how high should we set the bar?. <i>Archives of Internal Medicine</i> , 2012 , 172, 656-9; discussion 659		9
17	Freedom to innovate: the perils of centralized medical research-reply. <i>Archives of Internal Medicine</i> , 2012 , 172, 1692-3		
16	Holiday reading: The facts are the facts. <i>Cmaj</i> , 2012 , 184, 2029-30	3.5	
15	An unmeasured harm of screening. <i>Archives of Internal Medicine</i> , 2012 , 172, 1442-3		0
14	The apples and oranges of cost-effectiveness. <i>Cleveland Clinic Journal of Medicine</i> , 2012 , 79, 377-9	2.8	1
13	The conundrum of cost-effectiveness. <i>Cleveland Clinic Journal of Medicine</i> , 2012 , 79, 610-1	2.8	
12	Lacking the incentive to cure? Recurring <i>Clostridium difficile</i> diarrhea and our reluctance to use fecal transplantation. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 379-80	3	8
11	<i>Clostridium difficile</i> diarrhea and fecal transplantation. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 742-3	3	9
10	Caution needed when predicting problem residents. <i>Academic Medicine</i> , 2011 , 86, 2; author reply 2	3.9	2
9	Steroids in infection: an old wives' tale. <i>Cmaj</i> , 2011 , 183, 83; author reply 83-4	3.5	1
8	The frequency of medical reversal. <i>Archives of Internal Medicine</i> , 2011 , 171, 1675-6		74
7	The cardiovascular biomarker conundrum: challenges and solutions. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 2151-2	27.4	8
6	Perspective: Why There Must Be a Meditative Medicine. <i>Alternative and Complementary Therapies</i> , 2011 , 17, 274-278	0.3	
5	Are we treating professionalism professionally? Medical school behavior as predictors of future outcomes. <i>Teaching and Learning in Medicine</i> , 2011 , 23, 337-41	3.4	15
4	Reclaiming the morbidity and mortality conference: between Codman and Kundera. <i>Medical Humanities</i> , 2010 , 36, 108-11	1.4	14

3	Perspective: beyond storytelling in medicine: an encounter-based curriculum. <i>Academic Medicine</i> , 2010, 85, 794-8	3.9	8
2	Baseline event rate, the Concorde fallacy, and the topography of cardiac risk. <i>Medical Hypotheses</i> , 2010, 75, 639-41	3.8	1
1	General payments from Biogen to U.S. physicians between 2015 and 2020. <i>Journal of the American Geriatrics Society</i> ,	5.6	